Jacques F. Meis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8738248/publications.pdf

Version: 2024-02-01

550 38,642 papers citations

90 h-index 166 g-index

557 all docs 557
docs citations

557 times ranked

20984 citing authors

#	Article	IF	CITATIONS
1	South Asian (Clade I) <i>Candida auris</i> meningitis in a paediatric patient in Iran with a review of the literature. Mycoses, 2022, 65, 134-139.	4.0	20
2	Development of a Multiplex PCR Short Tandem Repeat Typing Scheme for Candida krusei. Journal of Clinical Microbiology, 2022, 60, JCM0203221.	3.9	9
3	A Chronic Autochthonous Fifth Clade Case of Candida auris Otomycosis in Iran. Mycopathologia, 2022, 187, 121-127.	3.1	18
4	Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance. Mycoses, 2022, 65, 303-311.	4.0	18
5	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe, The, 2022, 3, e464-e470.	7.3	35
6	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	7.3	255
7	Molecular characterisation of <i>Candida auris</i> isolates from immunocompromised patients in a tertiaryâ€care hospital in Kuwait reveals a novel mutation in <i>FKS1</i> conferring reduced susceptibility to echinocandins. Mycoses, 2022, 65, 331-343.	4.0	25
8	OUP accepted manuscript. Medical Mycology, 2022, , .	0.7	2
9	Emergence of <i>Candida auris</i> in intensive care units in Algeria. Mycoses, 2022, 65, 753-759.	4.0	10
10	Global prevalence and subgroup analyses of coronavirus disease (<scp>COVID</scp> â€19) associated <i>Candida auris</i> infections (<scp>CACa</scp>): A systematic review and metaâ€analysis. Mycoses, 2022, 65, 683-703.	4.0	37
11	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a Monophyletic <i>Fusarium</i> that Includes the <i>Fusarium solani</i> Species Complex. Phytopathology, 2021, 111, 1064-1079.	2.2	107
12	Cutibacterium acnes infections in revision surgery for persistent shoulder complaints: a retrospective cohort study. Archives of Orthopaedic and Trauma Surgery, 2021, 141, 197-205.	2.4	5
13	Activities of nine antifungal agents against Candida auris biofilms. Mycoses, 2021, 64, 381-384.	4.0	9
14	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
15	A pseudoâ€outbreak of Rhinocladiella similis in a bronchoscopy unit of a tertiary care teaching hospital in London, United Kingdom. Mycoses, 2021, 64, 394-404.	4.0	11
16	Ruling out underlying infection in 200 presumed aseptic knee and hip revision arthroplasties using a multiplex PCR system. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1283-1290.	2.9	2
17	COVID-19–Associated Pulmonary Aspergillosis, March–August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	4.3	175
18	Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 50.	3.5	28

#	Article	IF	CITATIONS
19	Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing. Journal of Fungi (Basel, Switzerland), 2021, 7, 81.	3.5	29
20	COVIDâ€19–associated pulmonary aspergillosis: a prospective singleâ€center dual case series. Mycoses, 2021, 64, 457-464.	4.0	48
21	Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Aspergillus flavus Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 164.	3.5	3
22	Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 154.	3.5	12
23	Clade-specific chromosomal rearrangements and loss of subtelomeric adhesins in $\langle i \rangle$ Candida auris $\langle i \rangle$. Genetics, 2021, 218, .	2.9	54
24	Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer. Frontiers in Cellular and Infection Microbiology, 2021, 11, 645049.	3.9	6
25	Environmental Detection of SARS-CoV-2 Virus RNA in Health Facilities in Brazil and a Systematic Review on Contamination Sources. International Journal of Environmental Research and Public Health, 2021, 18, 3824.	2.6	11
26	Taxonomy of the Trichophyton mentagrophytes/T. interdigitale Species Complex Harboring the Highly Virulent, Multiresistant Genotype T. indotineae. Mycopathologia, 2021, 186, 315-326.	3.1	76
27	Two Candida auris Cases in Germany with No Recent Contact to Foreign Healthcare—Epidemiological and Microbiological Investigations. Journal of Fungi (Basel, Switzerland), 2021, 7, 380.	3.5	6
28	Evaluation of DermaGenius < sup > ® < /sup > resistance realâ€time polymerase chain reaction for rapid detection of terbinafineâ€resistant <i>Trichophyton < /i> species. Mycoses, 2021, 64, 721-726.</i>	4.0	22
29	Axillary Digital Thermometers uplifted a multidrugâ€susceptible <i>Candidaauris</i> outbreak among COVIDâ€19 patients in Brazil. Mycoses, 2021, 64, 1062-1072.	4.0	40
30	MALDIâ€TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples. Mycoses, 2021, 64, 918-925.	4.0	7
31	Antifungal activity of nitroxoline against Candida auris isolates. Clinical Microbiology and Infection, 2021, 27, 1697.e7-1697.e10.	6.0	20
32	ECMM/ISHAM recommendations for clinical management of COVIDâ€19 associated mucormycosis in low― and middleâ€income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
33	Molecular typing and antifungal susceptibility study of Aspergillus spp. in intensive care unit (ICU) patients in Indonesia. Journal of Infection in Developing Countries, 2021, 15, 1014-1020.	1.2	4
34	Antifungal Susceptibility and Mutations in the Squalene Epoxidase Gene in Dermatophytes of the Trichophyton mentagrophytes Species Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0005621.	3.2	49
35	In vitro activities of 8 antifungal drugs against 126 clinical and environmental <i>Exophiala</i> isolates. Mycoses, 2021, 64, 1328-1333.	4.0	3
36	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The, 2021, 21, e246-e257.	9.1	167

#	Article	IF	CITATIONS
37	Basidiobolus omanensis sp. nov. Causing Angioinvasive Abdominal Basidiobolomycosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 653.	3.5	7
38	Diagnostic Allele-Specific PCR for the Identification of Candida auris Clades. Journal of Fungi (Basel,) Tj ETQq0 0 C) rgBT /Ov	erlgck 10 Tf 5
39	Disseminated Rhinocladiella mackenziei infection in a kidney transplant recipient: A case report and literature review. Journal De Mycologie Medicale, 2021, 31, 101196.	1.5	5
40	<i>In vitro</i> activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including <i>Penicillium</i> and <i>Talaromyces</i> species. Journal of Antimicrobial Chemotherapy, 2021, 76, 1229-1233.	3.0	23
41	Multi-locus sequence typing reveals genotypic similarity in Nigerian Cryptococcus neoformans AFLP1/VNI of environmental and clinical origin. Journal of Medical Microbiology, 2021, 70, .	1.8	2
42	<i>In vitro</i> activity of eight antifungal drugs against <i>Chaetomiaceae</i> . Medical Mycology, 2021, 60, .	0.7	1
43	In vitro synergy of echinocandins with triazoles against fluconazole-resistant Candida parapsilosis complex isolates. Journal of Global Antimicrobial Resistance, 2020, 21, 331-334.	2.2	2
44	Candida auris—"Ten Years After― Journal of Fungi (Basel, Switzerland), 2020, 6, 2.	3.5	4
45	Candida blankii: an emerging yeast in an outbreak of fungaemia in neonates in Delhi, India. Clinical Microbiology and Infection, 2020, 26, 648.e5-648.e8.	6.0	20
46	In vitro characterization, ADME analysis, and histological and toxicological evaluation of BM1, a macrocyclic amidinourea active against azole-resistant Candida strains. International Journal of Antimicrobial Agents, 2020, 55, 105865.	2.5	15
47	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
48	Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typing. Mycoses, 2020, 63, 284-293.	4.0	12
49	A Cluster of Candida auris Blood Stream Infections in a Tertiary Care Hospital in Oman from 2016 to 2019. Antibiotics, 2020, 9, 638.	3.7	24
50	Clonal Expansion of Environmental Triazole Resistant Aspergillus fumigatus in Iran. Journal of Fungi (Basel, Switzerland), 2020, 6, 199.	3.5	16
51	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	3.5	7
52	Molecular Epidemiology of Candida Auris Outbreak in a Major Secondary-Care Hospital in Kuwait. Journal of Fungi (Basel, Switzerland), 2020, 6, 307.	3.5	33
53	No to <i>Neocosmospora</i> : Phylogenomic and Practical Reasons for Continued Inclusion of the Fusarium solani Species Complex in the Genus <i>Fusarium</i> . MSphere, 2020, 5, .	2.9	61
54	Evaluation of Microsatellite Typing, ITS Sequencing, AFLP Fingerprinting, MALDI-TOF MS, and Fourier-Transform Infrared Spectroscopy Analysis of Candida auris. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Ov	veslosck 10) T £5 0 57 Td (

#	Article	IF	Citations
55	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	13.3	7 5
56	Development of Candida auris Short Tandem Repeat Typing and Its Application to a Global Collection of Isolates. MBio, 2020, 11 , .	4.1	56
57	Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report. Journal of Fungi (Basel, Switzerland), 2020, 6, 79.	3 . 5	88
58	Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. International Journal of Antimicrobial Agents, 2020, 56, 106049.	2.5	30
59	Paradoxal Trends in Azole-Resistant <i>Aspergillus fumigatus</i> in a National Multicenter Surveillance Program, the Netherlands, 2013–2018. Emerging Infectious Diseases, 2020, 26, 1447-1455.	4.3	46
60	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
61	Outbreak of <i>Dirkmeia churashimaensis</i> Fungemia in a Neonatal Intensive Care Unit, India. Emerging Infectious Diseases, 2020, 26, 764-768.	4.3	7
62	Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates. Mycopathologia, 2020, 185, 357-365.	3.1	6
63	International Society for Human and Animal Mycology (ISHAM)—New Initiatives. Journal of Fungi (Basel, Switzerland), 2020, 6, 97.	3. 5	4
64	Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: A nationwide study. Medical Mycology, 2020, 58, 859-866.	0.7	16
65	First azoleâ€resistant <i>Aspergillus fumigatus</i> isolates with the environmental TR ₄₆ /Y121F/T289A mutation in Iran. Mycoses, 2020, 63, 430-436.	4.0	29
66	Epidemiological features of nosocomial candidaemia in neonates, infants and children: A multicentre study in Iran. Mycoses, 2020, 63, 382-394.	4.0	34
67	Antifungal resistance in clinically significant fungi. Fungal Genetics and Biology, 2020, 139, 103369.	2.1	1
68	Burden of serious fungal infections in the Netherlands. Mycoses, 2020, 63, 625-631.	4.0	23
69	Donor-Derived Transmission of <i>Cryptococcus gattii</i> sensu lato in Kidney Transplant Recipients. Emerging Infectious Diseases, 2020, 26, 1329-1331.	4.3	6
70	Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital. Frontiers in Cellular and Infection Microbiology, 2020, 10, 232.	3.9	48
71	High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India. Journal of Fungi (Basel, Switzerland), 2020, 6, 67.	3.5	30
72	Occurrence of Cryptococcus neoformans and other yeast-like fungi in environmental sources in Bonaire (Dutch Caribbean). Germs, 2020, 10, 195-200.	1.3	3

#	Article	IF	CITATIONS
73	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.9	O
74	The Contribution of Genetic Variation of Streptococcus pneumoniae to the Clinical Manifestation of Invasive Pneumococcal Disease. Clinical Infectious Diseases, 2019, 68, 61-69.	5.8	21
75	Endophthalmitis caused by Purpureocillium lilacinum. Journal of Microbiology, Immunology and Infection, 2019, 52, 170-171.	3.1	7
76	In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species. Mycopathologia, 2019, 184, 607-613.	3.1	24
77	Potential Fifth Clade of <i>Candida auris, </i> Iran, 2018. Emerging Infectious Diseases, 2019, 25, 1780-1781.	4.3	257
78	Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. Journal of Antimicrobial Chemotherapy, 2019, 74, 2950-2958.	3.0	12
79	Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. Journal of Fungi (Basel, Switzerland), 2019, 5, 55.	3.5	149
80	ECMM <i>Candi</i> Regâ€"A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
81	External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris. Journal of Fungi (Basel, Switzerland), 2019, 5, 94.	3.5	11
82	Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry. Journal of Fungi (Basel, Switzerland), 2019, 5, 103.	3.5	8
83	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
84	Evaluation One Year after DAIR Treatment in 91 Suspected Early Prosthetic Joint Infections in Primary Knee and Hip Arthroplasty. Journal of Bone and Joint Infection, 2019, 4, 238-244.	1.5	17
85	A novel diagnosis scoring model to predict invasive pulmonary aspergillosis in the intensive care unit. Journal of King Abdulaziz University, Islamic Economics, 2019, 40, 140-146.	1.1	7
86	Ongoing Challenges with Healthcare-Associated Candida auris Outbreaks in Oman. Journal of Fungi (Basel, Switzerland), 2019, 5, 101.	3.5	34
87	<i>cyp51A</i> Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
88	A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. Fungal Genetics and Biology, 2019, 133, 103266.	2.1	93
89	The First Two Cases of CandidaÂauris in The Netherlands. Journal of Fungi (Basel, Switzerland), 2019, 5, 91.	3.5	18
90	Nontypeable Haemophilus influenzae Invasive Blood Isolates Are Mainly Phosphorylcholine Negative and Show Decreased Complement-Mediated Killing That Is Associated with Lower Binding of IgM and CRP in Comparison to Colonizing Isolates from the Oropharynx. Infection and Immunity, 2019, 87, .	2.2	12

#	Article	IF	Citations
91	Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS. Frontiers in Cellular and Infection Microbiology, 2019, 9, 20.	3.9	48
92	A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant Aspergillus fumigatus. Molecular Biology Reports, 2019, 46, 4537-4543.	2.3	7
93	Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency. Journal of Clinical Immunology, 2019, 39, 462-469.	3.8	34
94	Does Online Search Behavior Coincide with Candida auris Cases? An Exploratory Study. Journal of Fungi (Basel, Switzerland), 2019, 5, 44.	3.5	3
95	Brazil is so far free from Candida auris. Are we missing something?. Brazilian Journal of Infectious Diseases, 2019, 23, 149-150.	0.6	2
96	Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen. Biomolecules, 2019, 9, 205.	4.0	31
97	Nonrandom Distribution of Azole Resistance across the Global Population of Aspergillus fumigatus. MBio, 2019, 10, .	4.1	71
98	In vitro activity of nine antifungal agents against a global collection of Hortaea werneckii isolates, the agent of tinea nigra. International Journal of Antimicrobial Agents, 2019, 54, 95-98.	2.5	7
99	Microsatellite Stability in STR Analysis Aspergillus fumigatus Depends on Number of Repeat Units. Frontiers in Cellular and Infection Microbiology, 2019, 9, 82.	3.9	14
100	One year prospective survey of azole resistance in Aspergillus fumigatus at a French cystic fibrosis reference centre: prevalence and mechanisms of resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 1884-1889.	3.0	19
101	Fungicide-driven alterations in azole-resistant <i>Aspergillus fumigatus</i> are related to vegetable crops in Colombia, South America. Mycologia, 2019, 111, 217-224.	1.9	34
102	Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil. Frontiers in Microbiology, 2019, 10, 737.	3.5	49
103	Extensive tinea capitis and corporis in a child caused by TrichophytonÂverrucosum. Journal De Mycologie Medicale, 2019, 29, 62-66.	1.5	9
104	Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clinical Microbiology and Infection, 2019, 25, 799-806.	6.0	128
105	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1704-1712.	3.0	25
106	Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India. Journal of Antimicrobial Chemotherapy, 2019, 74, 1260-1268.	3.0	61
107	Killing of <i>Candida auris</i> by <scp>UV</scp> : Importance of exposure time and distance. Mycoses, 2019, 62, 408-412.	4.0	49
108	<i>Candida auris</i> in an Intensive Care Setting. New England Journal of Medicine, 2019, 380, 890-891.	27.0	7

#	Article	IF	CITATIONS
109	<p>Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline?</p> . Infection and Drug Resistance, 2019, Volume 12, 3727-3737.	2.7	24
110	<i>Candida auris</i> otomycosis in Iran and review of recent literature. Mycoses, 2019, 62, 101-105.	4.0	75
111	An unusual case of gastrointestinal basidiobolomycosis mimicking colon cancer; literature and review. Journal De Mycologie Medicale, 2019, 29, 75-79.	1.5	21
112	<i>ERG6</i> and <i>ERG2</i> Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical <i>Candida glabrata</i> Isolates in Kuwait. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	44
113	Invasive Infections Due to <i>Trichosporon</i> : Species Distribution, Genotyping, and Antifungal Susceptibilities from a Multicenter Study in China. Journal of Clinical Microbiology, 2019, 57, .	3.9	49
114	Perspectives on misidentification of <i>Trichophyton interdigitale</i> /i>/richophyton mentagrophytes using internal transcribed spacer region sequencing: Urgent need to update the sequence database. Mycoses, 2019, 62, 11-15.	4.0	40
115	Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients – A Dutch, multicentre study. Journal of Cystic Fibrosis, 2019, 18, 221-226.	0.7	55
116	Epidemiology of <i>Aspergillus</i> species causing keratitis in Mexico. Mycoses, 2019, 62, 144-151.	4.0	25
117	High-resolution fingerprinting of Candida parapsilosis isolates suggests persistence and transmission of infections among neonatal intensive care unit patients in Kuwait. Scientific Reports, 2019, 9, 1340.	3.3	23
118	Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris. Current Medical Mycology, 2019, 5, 26-30.	0.8	6
119	Comparative virulence of <i>Candida auris</i> with <i>Candida haemulonii</i> , <i> Candida glabrata</i> and <i>Candida albicans</i> in a murine model. Mycoses, 2018, 61, 377-382.	4.0	98
120	Fusarium metavorans sp. nov.: The frequent opportunist â€~FSSC6'. Medical Mycology, 2018, 56, S144-S152.	0.7	15
121	Postâ€influenzal triazoleâ€resistant aspergillosis following allogeneic stem cell transplantation. Mycoses, 2018, 61, 570-575.	4.0	15
122	High terbinafine resistance in <i>Trichophyton interdigitale</i> isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses, 2018, 61, 477-484.	4.0	237
123	An outbreak due to <i>Candida auris</i> with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses, 2018, 61, 498-505.	4.0	236
124	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
125	Emergence of azole resistant <i>Aspergillus fumigatus</i> and One Health: time to implement environmental stewardship. Environmental Microbiology, 2018, 20, 1299-1301.	3.8	47
126	Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study. Medical Mycology, 2018, 56, 406-415.	0.7	20

#	Article	IF	Citations
127	Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	32
128	Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 2018, 18, 24.	2.9	86
129	Environmental distribution of <i>Cryptococcus</i> species and some other yeastâ€ike fungi in India. Mycoses, 2018, 61, 305-313.	4.0	21
130	Differential Kinetics of Aspergillus nidulans and Aspergillus fumigatus Phagocytosis. Journal of Innate Immunity, 2018, 10, 145-160.	3.8	16
131	Differential In Vitro Cytokine Induction by the Species of Cryptococcus gattii Complex. Infection and Immunity, 2018, 86, .	2.2	7
132	A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 891-899.	3.0	380
133	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses, 2018, 61, 326-330.	4.0	60
134	Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients. Microbial Pathogenesis, 2018, 115, 353-357.	2.9	9
135	Airway persistence by the emerging multiâ€azoleâ€resistant <i>Rasamsonia argillacea</i> complex in cystic fibrosis. Mycoses, 2018, 61, 665-673.	4.0	13
136	In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions. Diagnostic Microbiology and Infectious Disease, 2018, 91, 266-268.	1.8	8
137	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.7	114
138	Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
139	Current antifungal treatment of fusariosis. International Journal of Antimicrobial Agents, 2018, 51, 326-332.	2.5	83
140	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Journal of Antimicrobial Chemotherapy, 2018, 73, 134-142.	3.0	29
141	Molecular Characterization and Antifungal Susceptibility Testing of Sequentially Obtained Clinical Cryptococcus deneoformans and Cryptococcus neoformans Isolates from Ljubljana, Slovenia. Mycopathologia, 2018, 183, 371-380.	3.1	15
142	Molecular Diagnostics of Arthroconidial Yeasts, Frequent Pulmonary Opportunists. Journal of Clinical Microbiology, 2018, 56, .	3.9	25
143	Use of cell surface protein typing for genotyping of azoleâ€resistant and â€susceptible <i>Aspergillus fumigatus</i> isolates in Iran. Mycoses, 2018, 61, 143-147.	4.0	8
144	Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22

#	Article	IF	CITATIONS
145	Cerebral phaeohyphomycosis due to <i>Rhinocladiella mackenziei</i> in Persian Gulf region: A case and review. Mycoses, 2018, 61, 261-265.	4.0	17
146	In vitro antifungal activity of amphotericin B and 11 comparators against <i>Aspergillus terreus</i> species complex. Mycoses, 2018, 61, 134-142.	4.0	29
147	The world's ten most feared fungi. Fungal Diversity, 2018, 93, 161-194.	12.3	85
148	Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 129.	3.5	29
149	Candida auris: a global fungal public health threat. Lancet Infectious Diseases, The, 2018, 18, 1298-1299.	9.1	69
150	Comparative genotyping and phenotyping of Aspergillus fumigatus isolates from humans, dogs and the environment. BMC Microbiology, 2018, 18, 118.	3.3	14
151	Genotyping of Aspergillus fumigatus in Formalin-Fixed Paraffin-Embedded Tissues and Serum Samples From Patients With Invasive Aspergillosis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 377.	3.9	5
152	Molecular epidemiology of environmental Cryptococcus species isolates based on amplified fragment length polymorphism. Journal De Mycologie Medicale, 2018, 28, 599-605.	1.5	16
153	Frequency and Geographic Distribution of CARD9 Mutations in Patients With Severe Fungal Infections. Frontiers in Microbiology, 2018, 9, 2434.	3.5	78
154	Low $\langle i \rangle$ In Vitro $\langle i \rangle$ Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
155	Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates. Journal of Fungi (Basel, Switzerland), 2018, 4, 103.	3.5	38
156	Mycotic Keratitis Caused by Fusarium solani sensu stricto (FSSC5): A Case Series. Mycopathologia, 2018, 183, 835-840.	3.1	9
157	Internal validation of <scp>GPS</scp> ^{â,,¢} <scp>MONODOSE</scp> CanAur dtecâ€ <scp>qPCR</scp> kit following the <scp>UNE</scp> / <scp>EN ISO</scp> / <scp>IEC</scp> 17025:2005 for detection of the emerging yeast <i>Candida auris</i> . Mycoses, 2018, 61, 877-884.	4.0	28
158	Adjunctive interferon-Î ³ immunotherapy in a pediatric case of Aspergillus terreus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1915-1922.	2.9	11
159	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
160	Production of the Invasive Aspergillosis Biomarker Bis(methylthio)gliotoxin Within the Genus Aspergillus: In Vitro and in Vivo Metabolite Quantification and Genomic Analysis. Frontiers in Microbiology, 2018, 9, 1246.	3.5	10
161	Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950–2017: protocol for a systematic review. BMJ Open, 2018, 8, e020654.	1.9	20
162	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52

#	Article	IF	Citations
163	Candida auris. Current Opinion in Infectious Diseases, 2018, 31, 334-340.	3.1	62
164	Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. Journal of Medical Microbiology, 2018, 67, 560-569.	1.8	15
165	Severe Disseminated Phaeohyphomycosis in a Patient with Inherited CARD9 Deficiency. Archives of Clinical Infectious Diseases, $2018,13,.$	0.2	7
166	Phage-Derived Protein Induces Increased Platelet Activation and Is Associated with Mortality in Patients with Invasive Pneumococcal Disease. MBio, 2017, 8, .	4.1	24
167	<i>In Vitro</i> Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	30
168	Global Population Genetic Analysis of Aspergillus fumigatus. MSphere, 2017, 2, .	2.9	71
169	Molecular and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry-Based Characterization of Clinically Significant Melanized Fungi in India. Journal of Clinical Microbiology, 2017, 55, 1090-1103.	3.9	33
170	Imported Talaromycosis in Oman in Advanced HIV: A Diagnostic Challenge Outside the Endemic Areas. Mycopathologia, 2017, 182, 739-745.	3.1	11
171	Intercountry Transfer of Triazole-Resistant Aspergillus fumigatus on Plant Bulbs. Clinical Infectious Diseases, 2017, 65, 147-149.	5.8	63
172	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015. Clinical Infectious Diseases, 2017, 65, 216-225.	5.8	50
173	Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Scientific Reports, 2017, 7, 45631.	3.3	96
174	Low sensitivity of implant sonication when screening for infection in revision surgery. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 294-299.	3.3	40
175	<i>Fusarium</i> species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses, 2017, 60, 204-212.	4.0	26
176	Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment. Journal of Infectious Diseases, 2017, 216, S436-S444.	4.0	199
177	<i>In Vitro</i> Interactions of Echinocandins with Triazoles against Multidrug-Resistant <i>Candida auris</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	75
178	Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
179	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the <i>Cryptococcus</i> Genus. MSphere, 2017, 2, .	2.9	124
180	The first cases of <i>Candida auris</i> candidaemia in Oman. Mycoses, 2017, 60, 569-575.	4.0	66

#	Article	IF	CITATIONS
181	Neonatal Cutaneous Invasive Aspergillosis Accompanied by Hemophagocytic Lymphohistocytosis. Pediatric Infectious Disease Journal, 2017, 36, 423-425.	2.0	3
182	A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. MBio, $2017, 8, .$	4.1	104
183	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
184	Simultaneous Emergence of Multidrug-Resistant <i>Candida auris</i> on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical Infectious Diseases, 2017, 64, 134-140.	5.8	1,099
185	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
186	Routine identification of Nocardia species by MALDI-TOF mass spectrometry. Diagnostic Microbiology and Infectious Disease, 2017, 87, 7-10.	1.8	43
187	Home Environment as a Source of Life-Threatening Azole-Resistant <i>Aspergillus fumigatus</i> Immunocompromised Patients: Table 1 Clinical Infectious Diseases, 2017, 64, 76-78.	5.8	48
188	Ecoepidemiology of Cryptococcus gattii in Developing Countries. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Ove	erlgck 10 T	f 58 462 Td (
189	Whole Genome-Based Amplified Fragment Length Polymorphism Analysis Reveals Genetic Diversity in Candida africana. Frontiers in Microbiology, 2017, 8, 556.	3.5	19
190	Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathogens, 2017, 13, e1006290.	4.7	501
191	Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. Antimicrobial Resistance and Infection Control, 2017, 6, 93.	4.1	26
192	Antifungal Susceptibility Testing of Fusarium: A Practical Approach. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /O	iveglgck 10) Tf 50 302 To
193	Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	72
194	Microsatellite Genotyping of Candida parapsilosis Clinical Isolates. Current Medical Mycology, 2017, 3, 15-20.	0.8	6
195	Invasive pulmonary aspergillosis in immunocompetent patients acquired during renovation in a chest institute., 2017,,.		0
196	Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathogens, 2016, 12, e1005464.	4.7	314
197	Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?. PLoS Pathogens, 2016, 12, e1005491.	4.7	46
198	Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 2016, 59, 101-107.	4.0	36

#	Article	IF	Citations
199	Genotyping of clinical and environmental <i>Aspergillus flavus</i> isolates from Iran using microsatellites. Mycoses, 2016, 59, 220-225.	4.0	12
200	The Concept of Ecthyma Gangrenosum Illustrated by a Fusarium oxysporum Infection in an Immunocompetent Individual. Mycopathologia, 2016, 181, 759-763.	3.1	15
201	Comparison of biotyping methods as alternative identification tools to molecular typing of pathogenic <i><scp>C</scp>ryptococcus</i> <scp>Eaharan Africa. Mycoses, 2016, 59, 151-156.</scp>	4.0	9
202	Epidemiology and molecular mechanisms of antifungal resistance inÂ <i>Candida</i> and <i>Aspergillus</i> Mycoses, 2016, 59, 198-219.	4.0	142
203	Treatment of prosthetic joint infections due to <i> Propionibacterium </i> Nonthly Notices of the Royal Astronomical Society: Letters, 2016, 87, 60-66.	3.3	38
204	Identification and typing of the emerging pathogen <i>Candida auris</i> by matrixâ€assisted laser desorption ionisation time of flight mass spectrometry. Mycoses, 2016, 59, 535-538.	4.0	86
205	First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrobial Resistance and Infection Control, 2016, 5, 35.	4.1	535
206	Global molecular epidemiology and genetic diversity of <i>Fusarium</i> , a significant emerging group of human opportunists from 1958 to 2015. Emerging Microbes and Infections, 2016, 5, 1-11.	6.5	89
207	Clinical implications of globally emerging azole resistance in <i>Aspergillus fumigatus</i> Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150460.	4.0	243
208	Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. Journal of Infection, 2016, 72, 745-752.	3.3	31
209	<i>Candida haemulonii</i> species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	55
210	Are the TR ₄₆ /Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?. Antimicrobial Agents and Chemotherapy, 2016, 60, 3259-3260.	3.2	12
211	In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe. Diagnostic Microbiology and Infectious Disease, 2016, 86, 289-292.	1.8	12
212	Identification by Molecular Methods and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and Antifungal Susceptibility Profiles of Clinically Significant Rare Aspergillus Species in a Referral Chest Hospital in Delhi, India. Journal of Clinical Microbiology, 2016, 54, 2354-2364.	3.9	54
213	First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. Journal of Infection, 2016, 73, 369-374.	3.3	340
214	Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 6916-6919.	3.2	39
215	Azole resistance surveillance in <i>Aspergillus fumigatus</i> : beneficial or biased?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2079-2082.	3.0	49
216	Intra- and Interlaboratory Agreement in Assessing theln VitroActivity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods. Antimicrobial Agents and Chemotherapy, 2016, 60, 6173-6178.	3.2	15

#	Article	IF	Citations
217	In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infectious Diseases, The, 2016, 16, e251-e260.	9.1	123
218	Fusarium ramigenum, a novel human opportunist in a patient with common variable immunodeficiency and cellular immune defects: case report. BMC Infectious Diseases, 2016, 16, 79.	2.9	6
219	Molecular epidemiology and <i>in vitro</i> antifungal susceptibility testing of 108 clinical <i>Cryptococcus neoformans sensu lato</i> and <i>Cryptococcus gattii sensu lato</i> isolates from Denmark. Mycoses, 2016, 59, 576-584.	4.0	46
220	Geographically predominant genotypes of Aspergillus terreus species complex in Austria: s microsatellite typing study. Clinical Microbiology and Infection, 2016, 22, 270-276.	6.0	23
221	International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2016, 60, 1079-1084.	3.2	113
222	Discovery of a sexual cycle in <i>Talaromyces amestolkiae </i> . Mycologia, 2016, 108, 70-79.	1.9	8
223	<i>In vitro</i> combinations of natamycin with voriconazole, itraconazole and micafungin against clinical <i>Fusarium</i> strains causing keratitis: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, 953-955.	3.0	53
224	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Genus <i>Fusarium</i> Causing Human Keratomycosis in South India. Medical Mycology, 2016, 54, 287-294.	0.7	36
225	Bacteroides fragilis in biopsies of patients with major abscesses and diabetic foot infections: direct molecular versus culture-based detection. Diagnostic Microbiology and Infectious Disease, 2016, 85, 263-265.	1.8	3
226	Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clinical Microbiology and Infection, 2016, 22, 277.e1-277.e9.	6.0	127
227	Bipolaris oryzae, a novel fungal opportunist causing keratitis. Diagnostic Microbiology and Infectious Disease, 2016, 85, 61-65.	1.8	7
228	Azole Resistance in <i>Aspergillus fumigatus</i> : Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clinical Infectious Diseases, 2016, 62, 362-368.	5.8	468
229	DNA barcoding, MALDI-TOF, and AFLP data support Fusarium ficicrescens as a distinct species within the Fusarium fujikuroi species complex. Fungal Biology, 2016, 120, 265-278.	2.5	40
230	A novel quantitative PCR assay for the detection of Streptococcus pneumoniae using the competence regulator gene target comX. Journal of Medical Microbiology, 2016, 65, 129-136.	1.8	5
231	Cryptococcus neoformans population diversity and clinical outcomes of HIV-associated cryptococcal meningitis patients in Zimbabwe. Journal of Medical Microbiology, 2016, 65, 1281-1288.	1.8	28
232	Non-traumatic keratitis due to Colletotrichum truncatum. JMM Case Reports, 2016, 3, e005047.	1.3	4
233	Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. Journal of Antimicrobial Chemotherapy, 2015, 70, 1068-71.	3.0	81
234	The post-vaccine microevolution of invasive Streptococcus pneumoniae. Scientific Reports, 2015, 5, 14952.	3.3	36

#	Article	IF	Citations
235	Cryptococcal meningitis due to <i>Cryptococcus neoformans</i> genotype <scp>AFLP</scp> 1/ <scp>VNI</scp> in Iran: a review of the literature. Mycoses, 2015, 58, 689-693.	4.0	16
236	Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Frontiers in Microbiology, 2015, 06, 428.	3.5	89
237	Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Isolates in Delhi, India: Evidence of Genetic Diversity by Amplified Fragment Length Polymorphism and Microsatellite Typing. PLoS ONE, 2015, 10, e0118997.	2.5	53
238	Global Spread of Human Chromoblastomycosis Is Driven by Recombinant Cladophialophora carrionii and Predominantly Clonal Fonsecaea Species. PLoS Neglected Tropical Diseases, 2015, 9, e0004004.	3.0	21
239	Simple, Low-Cost Detection of Candida parapsilosis Complex Isolates and Molecular Fingerprinting of Candida orthopsilosis Strains in Kuwait by ITS Region Sequencing and Amplified Fragment Length Polymorphism Analysis. PLoS ONE, 2015, 10, e0142880.	2.5	44
240	Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. Journal of Antimicrobial Chemotherapy, 2015, 70, 1522-1526.	3.0	161
241	First Description of Azole-Resistant Aspergillus fumigatus Due to TR ₄₆ /Y121F/T289A Mutation in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 4331-4335.	3.2	61
242	Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrobial Agents and Chemotherapy, 2015, 59, 7882-7887.	3.2	41
243	Debridement, antibiotics and implant retention in early postoperative infection with Pseudomonas aeruginosa. Journal of Infection, 2015, 70, 307-309.	3.3	10
244	Debridement, antibiotics and implant retention in early postoperative infection with Enterococcus sp Clinical Microbiology and Infection, 2015, 21, e41-e42.	6.0	16
245	Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales. Antimicrobial Agents and Chemotherapy, 2015, 59, 1745-1750.	3.2	97
246	Fatal Disseminated Infection with Fusarium petroliphilum. Mycopathologia, 2015, 179, 119-124.	3.1	20
247	<i>In Vitro</i> Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 6642-6645.	3.2	10
248	Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathogens, 2015, 11, e1004884.	4.7	123
249	Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired?. Journal of Global Antimicrobial Resistance, 2015, 3, 69-74.	2.2	81
250	High prevalence of azole resistance in <i>Aspergillus fumigatus</i> isolates from high-risk patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 2894-2898.	3.0	92
251	Proximal subungual onychomycosis caused by <i>Fusarium falciforme</i> successfully cured with posaconazole. British Journal of Dermatology, 2015, 173, 253-255.	1.5	18
252	Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples. BMC Infectious Diseases, 2015, 15, 56.	2.9	23

#	Article	IF	CITATIONS
253	Hip and knee arthroplasty: quo vadis?. Antimicrobial Resistance and Infection Control, 2015, 4, 19.	4.1	2
254	Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2015, 59, 666-668.	3.2	58
255	Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 2855-2866.	3.2	60
256	Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. Journal of Clinical Microbiology, 2015, 53, 1823-1830.	3.9	409
257	Draft Genome Sequence of a Fluconazole-Resistant $\langle i \rangle$ Candida auris $\langle i \rangle$ Strain from a Candidemia Patient in India. Genome Announcements, 2015, 3, .	0.8	62
258	Genomic Context of Azole Resistance Mutations in Aspergillus fumigatus Determined Using Whole-Genome Sequencing. MBio, 2015, 6, e00536.	4.1	171
259	<i>In vitro</i> susceptibility patterns of clinically important <i>Trichophyton</i> and <i>Epidermophyton</i> species against nine antifungal drugs. Mycoses, 2015, 58, 303-307.	4.0	64
260	Multiâ€triazoleâ€resistant <i>Aspergillus fumigatus</i> infections in Australia. Mycoses, 2015, 58, 350-355.	4.0	89
261	A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. Antimicrobial Agents and Chemotherapy, 2015, 59, 6615-6619.	3.2	58
262	Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and <i>In Vivo</i> Impact in Infected Galleria mellonella Larvae. Antimicrobial Agents and Chemotherapy, 2015, 59, 6581-6587.	3.2	106
263	Direct molecular versus culture-based assessment of Gram-positive cocci in biopsies of patients with major abscesses and diabetic foot infections. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1885-1892.	2.9	14
264	In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 – 2015. BMC Microbiology, 2015, 15, 121.	3.3	31
265	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
266	<i>In Vitro</i> Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium. Antimicrobial Agents and Chemotherapy, 2015, 59, 7818-7822.	3.2	9
267	Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006–2008). Clinical Microbiology and Infection, 2015, 21, 87.e1-87.e10.	6.0	96
268	Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. Journal of Antimicrobial Chemotherapy, 2015, 70, 412-415.	3.0	55
269	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. Journal of Clinical Microbiology, 2015, 53, 1056-1062.	3.9	65
270	Cryptococcus gattii genotype AFLP6/VGII meningoencephalitis in an immunocompetent Filipino male in Kuwait: activation of a dormant infection. JMM Case Reports, 2015, 2, .	1.3	3

#	Article	IF	CITATIONS
271	Cryptococcus and Cryptococcosis in Cuba. A minireview. Mycoses, 2014, 57, 707-717.	4.0	15
272	Invasive Mycosis Due to Species of Blastobotrys in Immunocompromised Patients with Reduced Susceptibility to Antifungals. Journal of Clinical Microbiology, 2014, 52, 4094-4099.	3.9	9
273	Keratitis by Fusarium temperatum, a novel opportunist. BMC Infectious Diseases, 2014, 14, 588.	2.9	36
274	Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts. Open Forum Infectious Diseases, 2014, 1, ofu029.	0.9	23
275	<i>In Vitro</i> Antifungal Susceptibility Profile and Correlation of Mycelial and Yeast Forms of Molecularly Characterized Histoplasma capsulatum Strains from India. Antimicrobial Agents and Chemotherapy, 2014, 58, 5613-5616.	3.2	17
276	Passive Surveillance for Azole-Resistant <i>Aspergillus fumigatus</i> , United States, 2011–2013. Emerging Infectious Diseases, 2014, 20, 1498-1503.	4.3	76
277	Species boundaries and nomenclature of <i>Rhizopus arrhizus</i> (syn. <i>R. oryzae</i>). Mycoses, 2014, 57, 108-127.	4.0	56
278	Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. Journal of Antimicrobial Chemotherapy, 2014, 69, 2979-2983.	3.0	122
279	Different colonization patterns of Aspergillus terreus in patients with cystic fibrosis. Clinical Microbiology and Infection, 2014, 20, 327-333.	6.0	23
280	First neonatal case of fungaemia due to <i><scp>P</scp>seudozyma aphidis</i> and a global literature review. Mycoses, 2014, 57, 64-68.	4.0	25
281	Recognizing filamentous basidiomycetes as agents of human disease: A review. Medical Mycology, 2014, 52, 782-797.	0.7	76
282	Avidity of Antibodies against Infecting Pneumococcal Serotypes Increases with Age and Severity of Disease. Vaccine Journal, 2014, 21, 904-907.	3.1	12
283	Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. Journal of Antimicrobial Chemotherapy, 2014, 69, 2258-2264.	3.0	23
284	Molecular characterization and <i>in vitro</i> antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. Mycoses, 2014, 57, 97-107.	4.0	48
285	<i>In Vitro</i> Activities of Eight Antifungal Drugs against 104 Environmental and Clinical Isolates of Aureobasidium pullulans. Antimicrobial Agents and Chemotherapy, 2014, 58, 5629-5631.	3.2	22
286	Photodynamic fungicidal efficacy of hypericin and dimethyl methylene blue against azoleâ€resistant <i>Candida albicans</i> strains. Mycoses, 2014, 57, 35-42.	4.0	48
287	Multidrug-resistant endemic clonal strain of Candida auris in India. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 919-926.	2.9	303
288	Diagnostic value of serum pneumococcal DNA load during invasive pneumococcal infections. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1119-1124.	2.9	12

#	Article	IF	Citations
289	Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 265-271.	2.9	12
290	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clinical Microbiology and Infection, 2014, 20, 27-46.	6.0	383
291	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clinical Microbiology and Infection, 2014, 20, 1-4.	6.0	85
292	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	6.0	262
293	ESCMID†and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection, 2014, 20, 5-26.	6.0	547
294	Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2014, 58, 916-922.	3.2	42
295	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clinical Microbiology and Infection, 2014, 20, 76-98.	6.0	400
296	Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection, 2014, 42, 393-404.	4.7	58
297	Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole. Antimicrobial Agents and Chemotherapy, 2014, 58, 2006-2012.	3.2	96
298	Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity, 2014, 67, 1-10.	12.3	152
299	Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complex in respiratory secretions from cystic fibrosis patients. New Microbes and New Infections, 2014, 2, 72-78.	1.6	14
300	Uncommon opportunistic yeast bloodstream infections from Qatar. Medical Mycology, 2014, 52, 552-556.	0.7	59
301	Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium. Antimicrobial Agents and Chemotherapy, 2014, 58, 5877-5885.	3.2	61
302	Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. Journal of Antimicrobial Chemotherapy, 2014, 69, 555-557.	3.0	113
303	Roussoella percutanea, a novel opportunistic pathogen causing subcutaneous mycoses. Medical Mycology, 2014, 52, 689-698.	0.7	26
304	Multilocus sequence typing of <i>Candida africana</i> from patients with vulvovaginal candidiasis in New Delhi, India. Mycoses, 2014, 57, 544-552.	4.0	22
305	Interlaboratory Comparison of Sample Preparation Methods, Database Expansions, and Cutoff Values for Identification of Yeasts by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Using a Yeast Test Panel. Journal of Clinical Microbiology, 2014, 52, 3023-3029.	3.9	69
306	Molecular epidemiology and antifungal susceptibility of Serbian <i>Cryptococcus neoformans</i> isolates. Mycoses, 2014, 57, 380-387.	4.0	33

#	Article	IF	CITATIONS
307	Exploring azole antifungal drug resistance in <i>Aspergillus fumigatus</i> with special reference to resistance mechanisms. Future Microbiology, 2014, 9, 697-711.	2.0	118
308	Effects of 7-valent pneumococcal conjugate 1 vaccine on the severity of adult 2 bacteremic pneumococcal pneumonia. Vaccine, 2014, 32, 3989-3994.	3.8	10
309	Molecular characterization of Cryptococcus gattii genotype AFLP6/VGII isolated from woody debris of divi-divi (Caesalpinia coriaria), Bonaire, Dutch Caribbean. Revista Iberoamericana De Micologia, 2014, 31, 193-196.	0.9	12
310	Simple, Low-Cost Molecular Assays for TR34/L98H Mutations in the cyp51A Gene for Rapid Detection of Triazole-Resistant Aspergillus fumigatus Isolates. Journal of Clinical Microbiology, 2014, 52, 2223-2227.	3.9	20
311	Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environmental Research, 2014, 133, 20-26.	7.5	64
312	Allergic bronchopulmonary mycosis due to fungi other than <i>Aspergillus</i> : a global overview. Critical Reviews in Microbiology, 2014, 40, 30-48.	6.1	174
313	<i>Schizophyllum commune</i> as an emerging fungal pathogen: a review and report of two cases. Mycoses, 2013, 56, 1-10.	4.0	91
314	Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba. Mycopathologia, 2013, 175, 439-444.	3.1	20
315	Veronaea botryosa: Molecular Identification with Amplified Fragment Length Polymorphism (AFLP) and In vitro Antifungal Susceptibility. Mycopathologia, 2013, 175, 505-513.	3.1	22
316	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy, 2013, 43, 850-873.	2.9	666
317	Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India. Diagnostic Microbiology and Infectious Disease, 2013, 76, 46-50.	1.8	23
318	Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. Journal of Medical Microbiology, 2013, 62, 1763-1767.	1.8	41
319	Microbial profiling does not differentiate between childhood recurrent acute otitis media and chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology, 2013, 77, 488-493.	1.0	38
320	First environmental isolation of <i>Cryptococcus gattii</i> , genotype AFLP5, from India and a global review. Mycoses, 2013, 56, 222-228.	4.0	22
321	<i>In Vitro</i> Antifungal Susceptibility of Cladophialophora carrionii, an Agent of Human Chromoblastomycosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1974-1977.	3.2	26
322	Fatal Cryptococcus gattii genotype AFLP5 infection in an immunocompetent Cuban patient. Medical Mycology Case Reports, 2013, 2, 48-51.	1.3	15
323	Severe Disseminated Phaeohyphomycosis in an Immunocompetent Patient Caused by Veronaea botryosa. Mycopathologia, 2013, 175, 497-503.	3.1	44
324	New Clonal Strain of <i>Candida auris </i> , Delhi, India. Emerging Infectious Diseases, 2013, 19, 1670-1673.	4.3	320

#	Article	IF	Citations
325	Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health. PLoS Pathogens, 2013, 9, e1003633.	4.7	300
326	Clinical Significance of Filamentous Basidiomycetes Illustrated by Isolates of the Novel Opportunist Ceriporia lacerata from the Human Respiratory Tract. Journal of Clinical Microbiology, 2013, 51, 585-590.	3.9	37
327	Clinical Significance and Molecular Characterization of Nonsporulating Molds Isolated from the Respiratory Tracts of Bronchopulmonary Mycosis Patients with Special Reference to Basidiomycetes. Journal of Clinical Microbiology, 2013, 51, 3331-3337.	3.9	60
328	Identification and Typing of Isolates of Cyphellophora and Relatives by Use of Amplified Fragment Length Polymorphism and Rolling Circle Amplification. Journal of Clinical Microbiology, 2013, 51, 931-937.	3.9	21
329	Molecular Characterization and <i>In Vitro</i> Antifungal Susceptibility Profile of Schizophyllum commune, an Emerging Basidiomycete in Bronchopulmonary Mycoses. Antimicrobial Agents and Chemotherapy, 2013, 57, 2845-2848.	3.2	35
330	Subcutaneous phaeohyphomycosis caused by Exophiala equina, with susceptibility to eight antifungal drugs. Journal of Medical Microbiology, 2013, 62, 797-800.	1.8	24
331	Taxonomy and Antifungal Susceptibility of Clinically Important Rasamsonia Species. Journal of Clinical Microbiology, 2013, 51, 22-30.	3.9	43
332	Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?. Antimicrobial Agents and Chemotherapy, 2013, 57, 5836-5842.	3.2	192
333	Reply to "Implications of High Antifungal Susceptibility on Schizophyllum commune-Associated Allergy in Clinical Practice― Antimicrobial Agents and Chemotherapy, 2013, 57, 5784-5785.	3.2	3
334	Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2013, 57, 3823-3828.	3.2	82
335	Environmental study of azoleâ€resistant <i><scp>A</scp>spergillus fumigatus</i> with TR ₃₄ /L98H mutations in the <i>cyp51</i> A gene in <scp>I</scp> ran. Mycoses, 2013, 56, 659-663.	4.0	98
336	Microcalorimetry Assay for Rapid Detection of Voriconazole Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 5704-5706.	3.2	7
337	Taxonomy and epidemiology of <l>Mucor irregularis</l> , agent of chronic cutaneous mucormycosis. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2013, 30, 48-56.	4.4	69
338	Molecular Identification and Susceptibility Pattern of ClinicalNocardiaSpecies: Emergence ofNocardia crassostreaeas an Agent of Invasive Nocardiosis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e33-e38.	1.9	14
339	Ancient Dispersal of the Human Fungal Pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE, 2013, 8, e71148.	2.5	122
340	Cryptococcus gattii Induces a Cytokine Pattern That Is Distinct from Other Cryptococcal Species. PLoS ONE, 2013, 8, e55579.	2.5	36
341	Geographically Structured Populations of Cryptococcus neoformans Variety grubii in Asia Correlate with HIV Status and Show a Clonal Population Structure. PLoS ONE, 2013, 8, e72222.	2.5	83
342	New Clonal Strain of <i>Candida auris </i> , Delhi, India. Emerging Infectious Diseases, 2013, 19, .	4.3	0

#	Article	IF	Citations
343	Meningitis caused by <i>Filobasidium uniguttulatum </i> : case report and overview of the literature. Mycoses, 2012, 55, 105-109.	4.0	22
344	Autochthonous and Dormant <i>Cryptococcus gattii</i> li>Infections in Europe. Emerging Infectious Diseases, 2012, 18, 1618-1624.	4.3	132
345	Microsatellite Genotyping Clarified Conspicuous Accumulation of Candida parapsilosis at a Cardiothoracic Surgery Intensive Care Unit. Journal of Clinical Microbiology, 2012, 50, 3422-3426.	3.9	49
346	Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 2635-2642.	3.2	244
347	Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population. Journal of Clinical Microbiology, 2012, 50, 1918-1926.	3.9	53
348	Molecular Epidemiology of Aspergillus fumigatus Isolates Harboring the TR ₃₄ /L98H Azole Resistance Mechanism. Journal of Clinical Microbiology, 2012, 50, 2674-2680.	3.9	127
349	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales. Journal of Clinical Microbiology, 2012, 50, 66-75.	3.9	134
350	Environmental prevalence of <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> in India: An update. Critical Reviews in Microbiology, 2012, 38, 1-16.	6.1	70
351	A rare case of allergic bronchopulmonary mycosis caused byAlternaria alternata. Medical Mycology, 2012, 50, 890-896.	0.7	29
352	Multiple subcutaneous cysts due to <i>Exophiala spinifera</i> in an immunocompetent patient. Medical Mycology, 2012, 50, 207-213.	0.7	20
353	<i>In Vitro</i> Activities of Nine Antifungal Drugs against 81 Phialophora and Cyphellophora Isolates. Antimicrobial Agents and Chemotherapy, 2012, 56, 6044-6047.	3.2	20
354	First Human Case of Pulmonary Fungal Ball Due to a Perenniporia Species (a Basidiomycete). Journal of Clinical Microbiology, 2012, 50, 3786-3791.	3.9	14
355	Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine. Antimicrobial Agents and Chemotherapy, 2012, 56, 3107-3113.	3.2	129
356	High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874.	3.2	164
357	<i>In Vitro</i> Antifungal Activity of Isavuconazole against Madurella mycetomatis. Antimicrobial Agents and Chemotherapy, 2012, 56, 6054-6056.	3.2	45
358	Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. Journal of Antimicrobial Chemotherapy, 2012, 67, 362-366.	3.0	173
359	Molecular identification tools for sibling species of <i>Scedosporium </i> And <i>Pseudallescheria </i> Medical Mycology, 2012, 50, 497-508.	0.7	25
360	Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 5898-5906.	3.2	212

#	Article	IF	CITATIONS
361	Isothermal microcalorimetry: a novel method for real-time determination of antifungal susceptibility of Aspergillus species. Clinical Microbiology and Infection, 2012, 18, E241-E245.	6.0	32
362	Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagnostic Microbiology and Infectious Disease, 2012, 73, 57-64.	1.8	45
363	Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp Diagnostic Microbiology and Infectious Disease, 2012, 73, 330-337.	1.8	19
364	USA300 Methicillin-resistant Staphylococcus aureus in Cuba. Antimicrobial Resistance and Infection Control, 2012, 1, 2.	4.1	9
365	Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogenAspergillus fumigatus. Molecular Ecology, 2012, 21, 57-70.	3.9	65
366	Black yeast-like fungi associated with Lethargic Crab Disease (LCD) in the mangrove-land crab, Ucides cordatus (Ocypodidae). Veterinary Microbiology, 2012, 158, 109-122.	1.9	71
367	Environmental isolation and characterisation of <i>Cryptococcus</i> species from living trees in Havana city, Cuba. Mycoses, 2012, 55, e138-44.	4.0	26
368	Resistance of Asian Cryptococcus neoformans Serotype A Is Confined to Few Microsatellite Genotypes. PLoS ONE, 2012, 7, e32868.	2.5	42
369	Rapid Susceptibility Testing and Microcolony Analysis of Candida spp. Cultured and Imaged on Porous Aluminum Oxide. PLoS ONE, 2012, 7, e33818.	2.5	39
370	Clonal Expansion and Emergence of Environmental Multiple-Triazole-Resistant Aspergillus fumigatus Strains Carrying the TR34/L98H Mutations in the cyp51A Gene in India. PLoS ONE, 2012, 7, e52871.	2.5	180
371	Temperate Climate Niche for (i>Cryptococcus gattii (i>in Northern Europe. Emerging Infectious Diseases, 2012, 18, 172-174.	4.3	62
372	Fatal Cerebral Phaeohyphomycosis in an Immunocompetent Individual Due to Thielavia subthermophila. Journal of Clinical Microbiology, 2011, 49, 2336-2341.	3.9	15
373	In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagnostic Microbiology and Infectious Disease, 2011, 71, 370-377.	1.8	42
374	Cladophialophora psammophila, a novel species of Chaetothyriales with a potential use in the bioremediation of volatile aromatic hydrocarbons. Fungal Biology, 2011, 115, 1019-1029.	2.5	73
375	Fonsecaea multimorphosa sp. nov, a new species of Chaetothyriales isolated from a feline cerebral abscess. Fungal Biology, 2011, 115, 1066-1076.	2.5	39
376	Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist. Medical Mycology, 2011, 49, 819-824.	0.7	41
377	<i>In vitro</i> susceptibility of 188 clinical and environmental isolates of <i>Aspergillus flavus</i> for the new triazole isavuconazole and seven other antifungal drugs. Mycoses, 2011, 54, e583-9.	4.0	46
378	Reactivation of a Cryptococcus gattii infection in a cheetah (Acinonyx jubatus) held in the National Zoo, Havana, Cuba. Mycoses, 2011, 54, e889-e892.	4.0	15

#	Article	IF	Citations
379	Severe prosthetic joint infection in an immunocompetent male patient due to a therapy refractory <i>Pseudallescheria apiosperma </i> Mycoses, 2011, 54, 22-27.	4.0	26
380	Infection and colonisation due to <i>Scedosporium</i> in Northern Spain. An <i>in vitro</i> antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses, 2011, 54, 12-21.	4.0	35
381	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clinical Microbiology and Infection, 2011, 17, 1859-1867.	6.0	566
382	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, $2011,17,1-12$.	6.0	113
383	Molecular Epidemiology of Aspergillus fumigatus: an In-Depth Genotypic Analysis of Isolates Involved in an Outbreak of Invasive Aspergillosis. Journal of Clinical Microbiology, 2011, 49, 3498-3503.	3.9	51
384	High Resolution Genotyping of Clinical Aspergillus flavus Isolates from India Using Microsatellites. PLoS ONE, 2011, 6, e16086.	2.5	29
385	Microsatellite typing and susceptibilities of serial Cryptococcus neoformansisolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infectious Diseases, 2010, 10, 289.	2.9	32
386	Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. Journal of Antimicrobial Chemotherapy, 2010, 65, 901-905.	3.0	64
387	<i>Apophysomyces elegans</i> : Epidemiology, Amplified Fragment Length Polymorphism Typing, and <i>In Vitro</i> Antifungal Susceptibility Pattern. Journal of Clinical Microbiology, 2010, 48, 4580-4585.	3.9	67
388	<i>In Vitro</i> Activities of Eight Antifungal Drugs against 55 Clinical Isolates of <i>Fonsecaea</i> spp. Antimicrobial Agents and Chemotherapy, 2010, 54, 1636-1638.	3.2	57
389	In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 175-177.	3.0	26
390	First Autochthonous Case of <i>Rhinocladiella mackenziei</i> Cerebral Abscess Outside the Middle East. Journal of Clinical Microbiology, 2010, 48, 646-649.	3.9	36
391	The clinical spectrum of <i>Exophiala jeanselmei </i> , with a case report and <i>in vitro </i> antifungal susceptibility of the species. Medical Mycology, 2010, 48, 318-327.	0.7	43
392	Use of Amplified Fragment Length Polymorphism To Identify 42 <i>Cladophialophora</i> Strains Related to Cerebral Phaeohyphomycosis with In Vitro Antifungal Susceptibility. Journal of Clinical Microbiology, 2010, 48, 2350-2356.	3.9	55
393	<i>Rhinocladiella aquaspersa</i> , proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Medical Mycology, 2010, 48, 696-703.	0.7	55
394	Subcutaneous phaeohyphomycotic cyst caused by <i>Pyrenochaeta romeroi</i> . Medical Mycology, 2010, 48, 763-768.	0.7	37
395	<i>In Vitro</i> Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental <i>Cryptococcus gattii</i> Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 5139-5145.	3.2	121
396	The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Medical Mycology, 2010, 48, 1-10.	0.7	37

#	Article	IF	Citations
397	Microsatellite Typing of Clinical and Environmental Cryptococcus neoformans var. grubii Isolates from Cuba Shows Multiple Genetic Lineages. PLoS ONE, 2010, 5, e9124.	2.5	51
398	In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species. Journal of Antimicrobial Chemotherapy, 2009, 63, 1295-1297.	3.0	24
399	Moulds and man. Journal of Antimicrobial Chemotherapy, 2009, 63, i21-i22.	3.0	7
400	Molecular Identification and Susceptibility of <i>Trichosporon </i> Species Isolated from Clinical Specimens in Qatar: Isolation of <i>Trichosporon dohaense </i> Journal of Clinical Microbiology, 2009, 47, 1791-1799.	3.9	66
401	Interlaboratory reproducibility of a microsatellite-based typing assay for Aspergillus fumigatus through the use of allelic ladders: proof of concept. Clinical Microbiology and Infection, 2009, 15, 180-187.	6.0	52
402	Changing epidemiology of an emerging infection: zygomycosis. Clinical Microbiology and Infection, 2009, 15, 10-14.	6.0	73
403	Utility of CSP typing to sub-type clinical Aspergillus fumigatus isolates and proposal for a new CSP type nomenclature. Journal of Microbiological Methods, 2009, 77, 292-296.	1.6	36
404	Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 110-114.	0.7	41
405	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. Medical Mycology, 2009, 47, 802-807.	0.7	9
406	Molecular typing of <i>Aspergillus</i> species. Mycoses, 2008, 51, 463-476.	4.0	41
407	Utility of a microsatellite assay for identifying clonally related outbreak isolates of Aspergillus fumigatus. Journal of Microbiological Methods, 2008, 73, 252-256.	1.6	51
408	RespiFinder: a New Multiparameter Test To Differentially Identify Fifteen Respiratory Viruses. Journal of Clinical Microbiology, 2008, 46, 1232-1240.	3.9	112
409	Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 842-849.	3.9	96
410	In Vitro Activities at pH 5.0 and pH 7.0 and In Vivo Efficacy of Flucytosine against <i>Aspergillus fumigatus</i> . Antimicrobial Agents and Chemotherapy, 2008, 52, 4483-4485.	3.2	26
411	<i>Candida krusei</i> , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 515-521.	3.9	195
412	In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 <i>Cryptococcus neoformans</i> Isolates from Cuba. Antimicrobial Agents and Chemotherapy, 2008, 52, 1580-1582.	3.2	65
413	Candida nivariensis Isolated from an Indonesian Human Immunodeficiency Virus-Infected Patient Suffering from Oropharyngeal Candidiasis. Journal of Clinical Microbiology, 2008, 46, 388-391.	3.9	40
414	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology, 2007, 45, 1735-1745.	3.9	269

#	Article	IF	Citations
415	Comparison of Two Highly Discriminatory Molecular Fingerprinting Assays for Analysis of Multiple Aspergillus fumigatus Isolates from Patients with Invasive Aspergillosis. Journal of Clinical Microbiology, 2007, 45, 1415-1419.	3.9	61
416	Microsatellite based typing of Aspergillus fumigatus: Strengths, pitfalls and solutions. Journal of Microbiological Methods, 2007, 69, 268-272.	1.6	62
417	Retrotransposon insertion-site context (RISC) typing: A novel typing method for Aspergillus fumigatus and a convenient PCR alternative to restriction fragment length polymorphism analysis. Journal of Microbiological Methods, 2007, 70, 528-534.	1.6	22
418	Hand hygiene and health-care-associated infections. Lancet Infectious Diseases, The, 2007, 7, 304-305.	9.1	1
419	Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes. Mycoses, 2007, 50, 270-276.	4.0	23
420	Clostridium cadaveris bacteraemia: Two cases and review. Scandinavian Journal of Infectious Diseases, 2006, 38, 59-62.	1.5	17
421	Candida rugosa , an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 3578-3582.	3.9	88
422	Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 3551-3556.	3.9	160
423	A case of imported paracoccidioidomycosis: an awkward infection in the Netherlands. Medical Mycology, 2006, 44, 13-18.	0.7	29
424	<i>Burkholderia fungorum</i> Septicemia. Emerging Infectious Diseases, 2005, 11, 1115-1117.	4.3	41
425	Use of a Novel Panel of Nine Short Tandem Repeats for Exact and High-Resolution Fingerprinting of Aspergillus fumigatus Isolates. Journal of Clinical Microbiology, 2005, 43, 4112-4120.	3.9	230
426	Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Current Medical Research and Opinion, 2005, 21, 1535-1546.	1.9	22
427	Relationship between In Vitro Activities of Amphotericin B and Flucytosine and pH for Clinical Yeast and Mold Isolates. Antimicrobial Agents and Chemotherapy, 2005, 49, 3341-3346.	3.2	19
428	Genetic Relatedness between Pneumococcal Populations Originating from the Nasopharynx, Adenoid, and Tympanic Cavity of Children with Otitis Media. Journal of Clinical Microbiology, 2005, 43, 3140-3144.	3.9	19
429	Assessingin vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Medical Mycology, 2005, 43, 133-152.	0.7	99
430	In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction Models. Antimicrobial Agents and Chemotherapy, 2004, 48, 2007-2013.	3.2	34
431	Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue. Journal of Clinical Microbiology, 2004, 42, 1716-1718.	3.9	13
432	Effect of pH on the In Vitro Activities of Amphotericin B, Itraconazole, and Flucytosine against Aspergillus Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 3147-3150.	3.2	28

#	Article	IF	Citations
433	Pericarditis as complication of appendicitis. Annals of Thoracic Surgery, 2004, 78, 1086-1088.	1.3	5
434	An adult case of oral infection with Kingella kingae. International Journal of Oral and Maxillofacial Surgery, 2004, 33, 105-107.	1.5	10
435	Antifungal activity of human polymorphonuclear and mononuclear phagocytes against nonâ€∢i>fumigatus Aspergillus⟨ i> species. Mycoses, 2003, 46, 77-83.	4.0	24
436	In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 106-117.	3.2	234
437	Quality Control Limits for Fluconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue. Journal of Clinical Microbiology, 2003, 41, 3410-3412.	3.9	21
438	Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrobial Agents and Chemotherapy, 2003, 47, 3647-3650.	3.2	156
439	Interactions of human phagocytes with mouldsFusariumspp. andVerticilliumnigrescenspossessing different pathogenicity1. Medical Mycology, 2003, 41, 503-509.	0.7	12
440	Molecular Epidemiology of Aspergillus fumigatus Isolates Recovered from Water, Air, and Patients Shows Two Clusters of Genetically Distinct Strains. Journal of Clinical Microbiology, 2003, 41, 4101-4106.	3.9	131
441	In vitro susceptibilities of zygomycetes to conventional and new antifungals. Journal of Antimicrobial Chemotherapy, 2003, 51, 45-52.	3.0	299
442	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. Journal of Clinical Microbiology, 2002, 40, 2876-2885.	3.9	59
443	Nationwide Survey of In Vitro Activities of Itraconazole and Voriconazole against Clinical Aspergillus fumigatus Isolates Cultured between 1945 and 1998. Journal of Clinical Microbiology, 2002, 40, 2648-2650.	3.9	88
444	In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2002, 46, 3323-3326.	3.2	41
445	In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 62-68.	3.2	230
446	Identification of Four Distinct Genotypes of Candida dubliniensis and Detection of Microevolution In Vitro and In Vivo. Journal of Clinical Microbiology, 2002, 40, 556-574.	3.9	77
447	In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents. Antimicrobial Agents and Chemotherapy, 2002, 46, 2708-2711.	3.2	78
448	Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis. Antimicrobial Agents and Chemotherapy, 2002, 46, 1953-1959.	3.2	50
449	Comparison of Fractional Inhibitory Concentration Index with Response Surface Modeling for Characterization of In Vitro Interaction of Antifungals against Itraconazole-Susceptible and -Resistant Aspergillus fumigatus Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 702-707.	3.2	53
450	In Vitro Interaction of Flucytosine Combined with Amphotericin B or Fluconazole against Thirty-Five Yeast Isolates Determined by both the Fractional Inhibitory Concentration Index and the Response Surface Approach. Antimicrobial Agents and Chemotherapy, 2002, 46, 2982-2989.	3.2	74

#	Article	IF	Citations
451	Method for Measuring Postantifungal Effect in Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 1960-1965.	3.2	24
452	In Vitro Activities of Pentamidine, Pyrimethamine, Trimethoprim, and Sulfonamides against Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 2029-2031.	3.2	23
453	Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clinical Infectious Diseases, 2002, 34, 7-14.	5.8	2,255
454	Pharmacological agents in development for invasive aspergillosis. Expert Opinion on Emerging Drugs, 2002, 7, 33-45.	2.4	3
455	Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transplant Infectious Disease, 2002, 4, 64-65.	1.7	18
456	Hyaluronic acid-based agents do not affect anastomotic strength in the rat colon, in either the presence or absence of bacterial peritonitis. British Journal of Surgery, 2002, 87, 1222-1228.	0.3	24
457	Current Management of Fungal Infections. Drugs, 2001, 61, 13-25.	10.9	80
458	Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. Journal of Hospital Infection, 2001, 47, 143-148.	2.9	95
459	A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagnostic Microbiology and Infectious Disease, 2001, 40, 27-33.	1.8	126
460	Cystatin M/E Expression is Restricted to Differentiated Epidermal Keratinocytes and Sweat Glands: a New Skin-Specific Proteinase Inhibitor that is a Target for Cross-Linking by Transglutaminase. Journal of Investigative Dermatology, 2001, 116, 693-701.	0.7	94
461	The Plasmodium falciparum knob-associated PfEMP3 antigen is also expressed at pre-erythrocytic stages and induces antibodies which inhibit sporozoite invasion. Molecular and Biochemical Parasitology, 2001, 112, 253-261.	1.1	19
462	Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 4256-4263.	3.9	71
463	Colorimetric Assay for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 3402-3408.	3.9	148
464	Phagocytosis and Killing of Candida albicans by Human Neutrophils After Exposure to Structurally Different Lipid Emulsions. Journal of Parenteral and Enteral Nutrition, 2001, 25, 9-13.	2.6	33
465	Analysis of Growth Characteristics of Filamentous Fungi in Different Nutrient Media. Journal of Clinical Microbiology, 2001, 39, 478-484.	3.9	168
466	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. Aids, 2001, 15, 1067-1068.	2.2	7
467	Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clinical Microbiology and Infection, 2000, 6, 336-337.	6.0	39
468	In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs. Mycoses, 2000, 43, 309-312.	4.0	28

#	Article	IF	CITATIONS
469	Microbiological diagnosis of invasive fungal infections in transplant recipients. Transplant Infectious Disease, 2000, 2, 80-87.	1.7	39
470	Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transplant Infectious Disease, 2000, 2, 96-98.	1.7	21
471	Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature Medicine, 2000, 6, 1258-1263.	30.7	165
472	Procalcitonin Does Not Discriminate Infection from Inflammation after Allogeneic Bone Marrow Transplantation. Vaccine Journal, 2000, 7, 889-892.	2.6	49
473	In Vitro Interaction of Terbinafine with Itraconazole against Clinical Isolates of Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2000, 44, 470-472.	3.2	105
474	A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagnostic Microbiology and Infectious Disease, 2000, 36, 215-223.	1.8	63
475	Prophylaxis and treatment of fungal infections associated with haematological malignancies. International Journal of Antimicrobial Agents, 2000, 15, 159-168.	2.5	21
476	Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. Aids, 2000, 14, 2787-2788.	2.2	60
477	Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology, 1999, 37, 419-426.	0.7	62
478	Prevention of Intra-abdominal Abscesses and Adhesions Using a Hyaluronic Acid Solution in a Rat Peritonitis Model. Archives of Surgery, 1999, 134, 997.	2.2	60
479	Fasâ€FasL Interactions Modulate Host Defense against SystemicCandida albicansInfection. Journal of Infectious Diseases, 1999, 180, 1648-1655.	4.0	18
480	Nosocomial fungal infections: candidemia. Diagnostic Microbiology and Infectious Disease, 1999, 34, 213-220.	1.8	148
481	Swelling of hand and forearm caused by Mycobacterium bovis. Netherlands Journal of Medicine, 1999, 54, 70-72.	0.5	5
482	Reply to Letter to the Editor of J.H. van Loenhout-Rooyackers [published in the September issue of The Netherlands Journal of Medicine (1999;55:163)]. Netherlands Journal of Medicine, 1999, 55, 249.	0.5	0
483	INVASIVE ASPERGILLOSIS IN TWO PATIENTS WITH PEARSON SYNDROME. Pediatric Infectious Disease Journal, 1999, 18, 739-741.	2.0	13
484	Delay in Administering the First Dose of Antibiotics in Patients Admitted to Hospital with Serious Infections. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 681-684.	2.9	41
485	Induction of SLPI (ALP/HUSI-I) in Epidermal Keratinocytes. Journal of Investigative Dermatology, 1998, 111, 996-1002.	0.7	99
486	Prevalence of antibodies to Histoplasma capsulatum among dutch speleologists. Journal of Infection, 1998, 37, 200-201.	3.3	0

#	Article	IF	CITATIONS
487	Sepsis puerperalis caused by a genotypically proven cat-derived Pasteurella multocida strain. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 76, 71-73.	1.1	8
488	Cefpirome: Epidemiological Survey in Intensive Care Units and Hematological Units in the Netherlands. Diagnostic Microbiology and Infectious Disease, 1998, 31, 489-491.	1.8	2
489	LOCAL EXPRESSION OF CYTOKINE mRNA IN SPLEEN AND PEYER'S PATCHES OF RATS IS INVOLVED IN RESISTANCE AGAINST INFECTION WITHYERSINIA ENTEROCOLITICA. Cytokine, 1998, 10, 206-212.	3.2	9
490	Functional and morphological monocyte abnormalities in a patient with malakoplakia. American Journal of Medicine, 1998, 105, 74-77.	1.5	76
491	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates Journal of Antimicrobial Chemotherapy, 1998, 42, 389-392.	3.0	71
492	Resistance of Aspergillus fumigatus to Itraconazole. Scandinavian Journal of Infectious Diseases, 1998, 30, 642-642.	1.5	6
493	Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiology and Infection, 1998, 120, 251-256.	2.1	84
494	Two-step polymerase chain reaction assay for detection of Yersinia species in general and of pathogenic Yersinia enterocolitica strains specifically. International Journal of Infectious Diseases, 1997, 1, 206-211.	3.3	3
495	Progress in fighting systemic fungal infections in haematological neoplasia. Supportive Care in Cancer, 1997, 6, 31-38.	2.2	27
496	Candidemia in intensive care unit patients: Risk factors for mortality. Infection, 1997, 25, 8-11.	4.7	121
497	Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection, 1997, 25, 86-89.	4.7	80
498	Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: Case report and review of the literature. Infection, 1997, 25, 109-111.	4.7	30
499	Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 26-28.	2.9	28
500	Analysis of an outbreak of puerperal fever due to group A streptococci by random amplified polymorphic DNA fingerprinting., 1997, 5, 232-236.		9
501	Analysis of an Outbreak of Puerperal Fever Due to Group A Streptococci by Random Amplified Polymorphic DNA Fingerprinting. Infectious Diseases in Obstetrics and Gynecology, 1997, 5, 232-236.	1.5	4
502	Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 909-912.	2.9	120
503	Epidemiological survey of an outbreak of multiresistantSerratia marcescens by PCR-fingerprinting. Infection, 1995, 23, 267-271.	4.7	22
504	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology, 1995, 70, 83-87.	1.8	36

#	Article	IF	CITATIONS
505	Interactions of Yersinia enterocolitica with polarized human intestinal Caco-2 cells. Medical Microbiology and Immunology, 1995, 184, 123-127.	4.8	6
506	Phylogenetic relationships of five species of <i>Aspergillus </i> and related taxa as deduced by comparison of sequences of small subunit ribosomal RNA. Medical Mycology, 1995, 33, 185-190.	0.7	27
507	Septic shock caused by group G \hat{l}^2 -haemolytic streptococci as presenting symptom of acute myeloid leukaemia. Netherlands Journal of Medicine, 1995, 46, 153-155.	0.5	12
508	Persistent Yersinia enterocolitica infection in three rat strains. Microbial Pathogenesis, 1995, 19, 57-63.	2.9	8
509	Cellulitis as First Clinical Presentation of Disseminated Cryptococcosis in Renal Transplant Recipients. Scandinavian Journal of Infectious Diseases, 1994, 26, 623-626.	1.5	29
510	Genotypic Characterization of Sequential Candida albicans Isolates from Fluconazole-Treated Neutropenic Patients. Journal of Infectious Diseases, 1994, 169, 1062-1070.	4.0	77
511	Endophthalmitis as presenting symptom of group G streptococcal endocarditis. Infection, 1994, 22, 56-57.	4.7	19
512	Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection, 1994, 22, 81-85.	4.7	54
513	Pneumopericardium complicating invasive pulmonary aspergillosis: Case report and review. Infection, 1994, 22, 102-105.	4.7	22
514	Fluconazole in the management of fungal urinary tract infections. Infection, 1994, 22, 247-251.	4.7	26
515	Polymerase chain reaction as a diagnostic tool for invasive aspergillosis: evaluation in bronchoalveolar lavage fluid from low risk patients. Serodiagnosis and Immunotherapy in Infectious Disease, 1994, 6, 203-208.	0.2	15
516	COLONIZATION OF THE FEMALE GENITAL TRACT WITH HAEMOPHILUS INFLUENZAE. Pediatric Infectious Disease Journal, 1994, 13, 758.	2.0	1
517	Multiple brain abscesses and bacteremia in a child due toFusobacterium necrophorum. Infection, 1993, 21, 174-176.	4.7	23
518	FatalClostridium perfringens meningitis associated with insertion of a ventriculo-peritoneal shunt. European Journal of Clinical Microbiology and Infectious Diseases, 1993, 12, 720-721.	2.9	12
519	Infections caused by Gemella morbillorum. Lancet, The, 1993, 342, 560.	13.7	54
520	CHRONIC POLYARTHRLTIS DUE TO PSEUDOMONAS AERUGINOSA. Rheumatology, 1993, 32, 1021-1022.	1.9	0
521	No Evidence for a Relation Between Borrelia burgdorferi Infection and Old Lesions of Localized Scleroderma (Morphea). Archives of Dermatology, 1993, 129, 386.	1.4	24
522	CROSS-INFECTION WITH PSEUDOMONAS AERUGINOSA IN A NEONATAL INTENSIVE CARE UNIT CHARACTERIZED BY POLYMERASE CHAIN REACTION FINGERPRINTING. Pediatric Infectious Disease Journal, 1993, 12, 1027-1028.	2.0	12

#	Article	IF	CITATIONS
523	PYOSALPINX CAUSED BY STREPTOCOCCUS PNEVMONIAE IN A YOUNG GIRL. Pediatric Infectious Disease Journal, 1993, 12, 539.	2.0	16
524	Fatal Intrauterine Infection Associated with Mycoplasma hominis. Clinical Infectious Diseases, 1992, 15, 753-754.	5.8	6
525	A scanning electron microscopic study of the sporogonic development of Plasmodium falciparum in Anopheles stephensi. Acta Tropica, 1992, 50, 227-236.	2.0	40
526	Localization of circumsporozoite protein in the sporogonic stages of Plasmodium vivax. Parasitology Research, 1992, 78, 165-167.	1.6	11
527	Erysipelas-like skin lesions associated withCampylobacter jejuni septicemia in patients with hypogammaglobulinemia. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 842-847.	2.9	67
528	Rapidly fatal Q-fever pneumonia in a patient with chronic granulomatous disease. Infection, 1992, 20, 287-289.	4.7	19
529	Fulminant Neonatal Sepsis due to Haemophilus influenzae. Scandinavian Journal of Infectious Diseases, 1991, 23, 649-652.	1.5	1
530	A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites. Molecular and Biochemical Parasitology, 1991, 45, 193-204.	1.1	59
531	Primary structure and localization of a conserved immunogenicPlasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Molecular and Biochemical Parasitology, 1991, 49, 119-131.	1.1	128
532	Detection of different developmental stages of malaria parasites by non-radioactive DNAin situ hybridization. The Histochemical Journal, 1991, 23, 109-115.	0.6	12
533	Bordetella bronchiseptica bronchitis in an immunosuppressed patient. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 366-367.	2.9	21
534	Non-CS pre-erythrocytic protective antigens. Immunology Letters, 1990, 25, 71-76.	2.5	45
535	Plasmodium falciparum: Studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Experimental Parasitology, 1990, 70, 1-11.	1.2	30
536	Plasmodium falciparum ookinetes migrate intercellularly through Anopheles stephensi midgut epithelium. Parasitology Research, 1989, 76, 13-19.	1.6	63
537	Ultrastructural studies on the interaction of Plasmodium falciparum ookinetes with the midgut epithelium of Anopheles stephensi mosquitoes. Zeitschrift FÃ $\frac{1}{4}$ r Parasitenkunde (Berlin, Germany), 1987, 73, 500-506.	0.8	61
538	Fine structure of the malaria parasite Plasmodium falciparum in human hepatocytes in vitro. Cell and Tissue Research, 1986, 244, 345-50.	2.9	30
539	Electron microscopic studies on the interaction of rat Kupffer cells and Plasmodium berghei sporozoites. Zeitschrift FÃ $^1\!\!/4$ r Parasitenkunde (Berlin, Germany), 1985, 71, 473-483.	0.8	30
540	Transformation of sporozoites of Plasmodium berghei into exoerythrocytic forms in the liver of its mammalian host. Cell and Tissue Research, 1985, 241, 353-360.	2.9	45

#	Article	IF	CITATIONS
541	Infection of cryopreserved adult human hepatocytes with sporozoites. Cell Biology International Reports, 1985, 9, 976.	0.6	11
542	The biology of tissue forms and other asexual stages in mammalian plasmodia. Experientia, 1984, 40, 1317-1329.	1.2	21
543	Histochemical observations on the exoerythrocytic malaria parasite Plasmodium berghei in rat liver. Histochemistry, 1984, 81, 417-425.	1.9	15
544	Intranuclear localization of sporozoites. Cell Biology International Reports, 1984, 8, 1016.	0.6	5
545	Fine structure of exoerythrocytic forms in cultured primary rat hepatocytes. Cell Biology International Reports, 1984, 8, 755-765.	0.6	15
546	Malaria parasitesâ€"discovery of the early liver form. Nature, 1983, 302, 424-426.	27.8	66
547	The demonstration of Plasmodium berghei sporozoites in rat hepatocytes one hour after inoculation. Zeitschrift $F\tilde{A}^{1}\!\!/4$ r Parasitenkunde (Berlin, Germany), 1982, 67, 345-348.	0.8	5
548	Comparison of a few systems for the determination of saprobic and trophic degree on the basis of plankton data. Hydrobiologia, 1980, 70, 251-256.	2.0	1
549	Differential Pneumococcal Growth Features in Severe Invasive Disease Manifestations. Microbiology Spectrum, 0, , .	3.0	0
550	In vitro activity of 23 antifungal drugs against 54 clinical and environmental <i>Aspergillus oryzae</i> isolates. Mycoses, 0, , .	4.0	3